Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03203473
Title Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

renal cell carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Diego Moores Cancer Center La Jolla California 92093 United States Details
University of Chicago Medical Center Chicago Illinois 60637 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 United States Details
Lifespan Comprehensve Cancer Center Providence Rhode Island 02903 United States Details
University of Utah, Huntsman Cancer Center Salt Lake City Utah 84112 United States Details
Unviersity of Wisconsin Carbone Cancer Center Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field